Deciphera Pharmaceuticals LLC
1505 Wakarusa Drive
Lawrence
Kansas
66047
Tel: 785-838-3767
Fax: 785-838-3747
Website: http://www.deciphera.com/
Email: deciphera@deciphera.com
138 articles with Deciphera Pharmaceuticals LLC
-
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
9/18/2020
Deciphera Pharmaceuticals, Inc., announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST.
-
Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020
9/17/2020
- Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer - - Rebastinib Combined with Carboplatin was Well-tolerated in Patients with Metastatic Solid Tumors and Showed Initial Clinical Activity - WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of data from the ovarian
-
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
8/17/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine kinase inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumor (GIST).
-
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
-
Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
8/6/2020
Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40 th Annual Growth Conference
-
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
8/4/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical and corporate developments.
-
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020
7/29/2020
Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020.
-
Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
7/14/2020
QINLOCK is the First Approved Tyrosine Kinase Inhibitor Designed Specifically for GIST Regardless of Patients’ Mutational Status
-
Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
7/2/2020
Clinically Meaningful Benefit Observed in Patients Receiving QINLOCK Following Progression on Placebo - - Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall survival (OS) for patients who crossed over t
-
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
6/22/2020
QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in Global INVICTUS Phase 3 Study
-
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum
6/11/2020
Deciphera Pharmaceuticals, Inc. announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:40 PM ET.
-
Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology
6/8/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that The Lancet Oncology has published results from the INVICTUS pivotal Phase 3 study of QINLOCK in patients with fourth-line gastrointestinal stromal tumor (GIST).
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson
6/4/2020
QINLOCK (Ripretinib), FDA Approved for Treatment of Gastrointestinal Stromal Tumors (GIST), Available at Biologics by McKesson
-
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
-
Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific Program
5/29/2020
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2 clinical trial of rebastinib, the Company’s investigational orally administered, potent and selective
-
Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific Program
5/29/2020
Patients Receiving QINLOCK for Fourth-line GIST Reported Improved Quality of Life and Better Physical and Role Functioning Compared with a Decline in Placebo
-
Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
5/27/2020
Deciphera Pharmaceuticals, Inc., a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET.
-
AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™
5/26/2020
AmerisourceBergen, a global healthcare solutions leader, announced today that it has been selected by Deciphera Pharmaceuticals (Deciphera) to support QINLOCK (ripretinib). AmerisourceBergen is providing a unified commercialization approach for QINLOCK which was approved by the U.S. Food and Drug Administration (FDA) on Friday, May 15, 2020. QINLOCK is an orally administered kinase switch control inhibitor approved for
-
PANTHERx® Rare Pharmacy Selected by Deciphera Pharmaceuticals to Distribute QINLOCK™ (ripretinib), for Gastrointestinal Stromal Tumor (GIST) Patients
5/18/2020
PANTHERx® Rare Pharmacy announces that it has been selected by Deciphera Pharmaceuticals as a limited distribution partner for new drug QINLOCK™ (ripretinib)